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Drug efficacy and pharmacokinetics were assessed in 63
patients, aged 5 days to 30 years (mean 8 years), who
received flecainide acetate for control of resistant arrhyth-
mias . Doses of flecainide ranged from 5  to 225 mg/m 2 body
surface area per day (mean 141) in divided doses every 8 to
12 h and serum trough levels ranged from 0.10 to 0.  
µg/ml (mean 0 .36) .
Flecainide controlled or partially controlled arrhythmia
in 53 (84%) of the 63 patients   7 of 7 patients who had the
permanent form of junctional reciprocating tachycardia, 12
of 13 who had an atrial ectopic tachycardia, 10 of 10 who
had ventricular tachycardia and 18 of 25 patients who had
reentrant supraventricular tachycardia . Five of seven pa-
tients who had the latter arrhythmia were unsuccessfully
treated with fiecainide . They had Wolff-Parkinson-White
syndrome and developed asymptomatic, incessant, slower
orthodromic reciprocating tachycardia while receiving the
drug. Transient blurred vision was reported in three patients
and two patients had transient hyperactivity . No significant
hemodynamic side effects were seen in any patient .
Twenty-five patients underwent oral pharmacokinetic
investigation . Young infants (<1 year of age) had a mean
Flecainide acetate (Tambocor, 3M/Riker Labs) is a relatively
new benzamide derivative that has been classified as a New
York Heart Association functional class IC antiarrhythmic
agent . It is used for a wide range of tachyarrhythmias in
adults and only recently has been investigated for use in
pediatric patients (1-3) . In adults, flecainide appears to be
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plasma elimination half-life (11/2) approximating that (11
to 12 h) found in older children and healthy adults; children
aged 1 to 12 years had a shorter mean t 1/2 of 8 h . Dosing
schedules based on milligrams per square meter body sur-
face area correlated better with plasma flecainide levels than
did dosing based on milligrams per kilogram body weight .
In conclusion, 1) flecainide was effective pediatric ther-
apy for permanent junctional reciprocating tachycardia,
atrial ectopic and chaotic atrial tachycardia, ventricular
tachycardia and, in most patients, reentrant supra-
ventricular tachycardia ; 2) some patients with Wolff-
Parkinson-White syndrome developed asymptomatic inces-
sant slow supraventricular tachycardia while receiving
flecainide ; 3) flecainide resulted in rare side effects and no
negative hemodynamic effects in any patient ; 4) despite a
shorter elimination half-life, every 12 h dosing schedule
(with lower flecainide trough levels than usually seen in
adults) provided adequate arrhythmia control in 80% of
young patients aged I to 12 years ; and 5) further study of
oral flecainide pharmacokinetics is needed for patients < 1
year of age .
(J Am Coll Cardiol 1 8  ;14 185- 1)
185
more effective than quinidine, disopyramide, mexiletine,
tocainide and propafenone in suppressing ventricular ectopic
activity (4,5), and it has proved effective in the management
of reentrant supraventricular tachycardias complicating
Wolff-Parkinson-White syndrome (1,6) .
Infants and children may manifest entirely different drug
therapeutic/toxic ratios from those of adults and they have
differences in drug pharmacokinetics and pharmacodynam-
ics secondary to age, body size, protein binding and maturity
of systems responsible for drug metabolism and elimination .
These factors may then require changes in dosing schedules
and calculation of dose based on body surface area rather
than body weight (7) . Currently, flecainide can be legally
prescribed for children, but there are no established guide-
lines for its use in this group .
The purpose of this study was twofold   1) to evaluate the
0735-10 7/8 /$3 .50
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Table 1. Spectrum of Antiarrhythmic Efficacy of Flecainide
Acetate in 63 Patients
AET = atria) ectopic tachycardia ; AVNre = typical AV node reentrant
tachycardia   CAT = chaotic atrial tachycardia ; JET = junctional ectopic
tachycardia   PJRT = permanent form ofjunctional reciprocating tachycardia  
SVT = supraventricular tachycardia   Vent = ventricular ; WPW = Wolff-
Parkinson-White syndrome .
efficacy and clinical and laboratory variables of oral dosing
of flecainide acetate in the control of supraventricular and
ventricular tachyarrhythmias in a large series of children ;
and 2) to establish the pharmacokinetics of flecainide in
these patients to allow delineation of appropriate dosing
guidelines .
Methods
Patient data . The study group comprised 63 patients
ranging in age from 5 days to 30 years (mean 8 years) . Only
four patients, aged 1 , 26, 26 and 30 years, respectively,
were > 18 years of age . Of the remaining 5  patients, 13 were
 s~6 months, 7 >6 to 12 months, 25 > 1 to 12 years and 18 > 12
years of age . Patients with refractory tachyarrhythmias were
included in the study ; the spectrum of arrhythmias is shown
in Table 1 . With the exception of digoxin in I I cases, all
previous medications were discontinued a minimum of 5
elimination half-lives before administration of flecainide was
initiated . No patient had received amiodarone therapy . All
patients were admitted to the hospital for initiation of
flecainide therapy and either they were discharged after
steady state had been reached with control of their arrhyth-
mia or the drug was discontinued because of poor control or
proarrhythmia .
All patients had a daily physical examination, vital signs
were noted and the following laboratory tests were per-
formed on admission   complete blood count, urinalysis, liver
serum enzymes, determination of renal function chemistry
values and digoxin level (if applicable) . A baseline chest
radiograph, electrocardiogram (ECG), 24 h ECG Hotter
monitor, two-dimensional and M-mode echocardiogram and
treadmill test (by modified Bruce protocol in patients aged
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>5 years) were obtained . Patients were monitored by telem-
etry ECG throughout hospitalization and underwent contin-
uous 24 h Hotter monitoring .
Complete pharmacokinetic data were obtained in 26
patients (as described later), and an additional 37 were
studied for drug efficacy and had plasma flecainide trough
values obtained . All patients (>7 years old) and their parents
signed a consent form before administration of flecainide .
The protocol and consent forms were approved by the
Institutional Review Board of the Baylor College of Medi-
cine .
Initiation pharmacokinetics . Flecainide acetate (supplied
by 3M/Riker Laboratories, Inc .) was administered in a single
25 mg/m'- dose. Plasma flecainide levels were determined at
0, 30 and 60 min, and at 2, 4, 6, 8, 12 and 24 h after this first
dose (assay performed by Riker Labs) . The concentration of
flecainide in plasma and urine was measured by a selective
and sensitive high performance liquid chromatographic
method (8) . The lower limit for quantitation using this assay
was 10 ng/ml for plasma and 50 ng/ml for urine . In small
infants, the 30 min and 8 h determinations were eliminated to
reduce blood drawing . Urine was collected when possible
from 0 to 12 h and 12 to 24 h for analysis of urinary flecainide
excretion . Twenty-one patients underwent this protocol .
Maintenance flecainide . Twenty-four hours after the first
dose pharmacokinetics, maintenance oral therapy was initi-
ated. In the initial phase of the study, the starting dose of
flecainide was 50 mg/m 2 per day divided into two doses on a
schedule of every 12 h . Because this dose had little or no
effect on arrhythmia in the first four patients treated, all
subsequent patients were started at 100
Mg/M2
per day
divided into two doses on a schedule of every 12 h . Younger
patients who could not swallow a tablet were provided with
an oral suspension of the intravenous form of flecainide
mixed with cherry syrup to a concentration of 10 mg/ml .
(Stability of the drug in this suspension was confirmed by
Riker Laboratories .)
The drug tins considered effective if acute tachycardia
was terminated or if a  0% reduction of incessant arrhythmia
was seen on 24 h Hotter monitor . Partial control was defined
by 60% to  0% reduction of incessant tachyarrhythmia on
Hotter monitor or persistent tachycardia at a rate that was
appropriate for age or that did not result in hemodynamic
compromise or symptoms. Proarrhythmia was defined as
either presence of a new arrhythmia or increasing frequency
of the underlying arrhythmia . If arrhythmia control was
considered adequate, the patient was discharged on oral
flecainide therapy after final serum chemistry values, ECG,
echocardiogram and trough flecainide values were obtained .
Patients with inadequate control had their dose titrated
upward to 150 mg/m' per day, then 200 mg/m' per day every
five doses to an effective dose or until either proarrhythmia
occurred or flecainide was deemed unsuccessful . Patients
with paroxysmal tachyarrhythmia had the dose increased
Control
Total
Full Partial
None
sVT
WPW 10 1 16
Concealed WPW 6 I '
 
PJRT
6
I 0 7
AVNre 2 3 0 5
JET 0 0 I 1
AET
5 2 1 8
CAT 4 I 0 5
Atria) flutter 0 I
1 2
Vent tachycardia 7 3 0 10
Total 40 13 10 63
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until ECG evidence of drug effect (approximately 20% to
30% prolongation of the QRS complex) was seen . In the
latter third of the study period, flecainide levels were avail-
able with a 4 to 6 h turnaround time and patients with
paroxysmal arrhythmias had their final dose based on drug
level with long-term efficacy determined over the follow-up
period .
The majority of patients were maintained on a 12 h dosing
schedule of flecainide . Seven patients were changed to
dosing every 8 h (at the same total daily dose as with dosing
every 12 h) to manage clinical episodes of breakthrough
tachycardia at 10 to 12 h after a flecainide dose .
Withdrawal kinetics . Ten patients receiving long-term
oral flecainide therapy had withdrawal pharmacokinetic de-
terminations performed according to the protocol for initia-
tion kinetics . Patients were hospitalized for a 24 h period .
Follow-up . Patients were discharged with an ECG tele-
phone transmitter with standard instructions from our labo-
ratory. Patients from the Houston and Southeast Texas
areas were seen in follow-up at the Texas Children's Hospi-
tal at 1, 3 and 6 months after discharge or more frequently if
needed. Other patients were followed up by their local
pediatric cardiologist, who communicated data on serum
flecainide levels and continuing assessment of efficacy to
Houston . At each follow-up visit, serum flecainide levels
were obtained and an ECG . 24 h Holter monitor, echocar-
diogram and chest radiograph were performed . Optimally,
trough flecainide levels were obtained, but in the outpatient
setting this was not always possible so notation was made of
time after dose .
Pharmacokinetic analysis . The plasma concentration ver-
sus time data were fit by nonlinear regression to an open
one-compartment model with first-order absorption and
first-order elimination with use of the iterative computer
program PCNONLIN (Statistical Consultants, Inc .) . The
data were fit to the following equation  
C =
Ka FD
V(Ka-K)
where C = the plasma concentration, Ka = the apparent
first-order absorption rate constant, F = the fraction of the
dose absorbed, D = the dose, V = the apparent volume of
distribution, K = the first-order elimination rate constant
and t = time after dose . The value for F was assumed to be
1 . which has been demonstrated for flecainide ( ) . The area
under the curve, total body clearance or plasma clearance
(CIv) . terminal plasma elimination half-life (t 1/2) and the
time to maximal concentration (T max) of flecainide in plasma
were calculated by standard formulas . The maximal concen-
tration (C mdx ) of flecainide in plasma after a single dose was
calculated where t = T,,,. Initial estimates for V, Ka and K
were obtained using the computer program PKCALC (10) .
A comparison of pharmacokinetic values from children
grouped according to age was performed with a one-way
PERRY ET AL .
	
187
FLECAINIDE  EFFICACY AND PHARMACOKINETICS
Figure 1 . Proarrhythmia after second dose of flecainide at 150
mg/m' per day in a patient with intermittent pre-excitation . Su-
praventricular tachycardia occurs at 158/min (right) .
analysis of variance followed by t tests . A p value of <0 .05
was considered significant .
Results
Efficacy (Table 1)
Flecainide was effective (control or partial control) in 43
of 53 patients with supraventricular tachyarrhythmias and
there were definite differences in efficacy depending on
arrhythmia type .
Wolff-Parkinson-White syndrome and "concealed" Wolff-
Parkinson-White syndrome . The drug was helpful in 11 of 16
patients with Wolff-Parkinson-White syndrome and su-
praventricular tachycardia . The majority of these patients
had frequent episodes of tachycardia before administration
of flecainide ; of those with paroxysmal episodes who were
maintained on flecainide, the follow-up period ranged from 7
to 14 months . In follow-up, pre-excitation persisted on the
surface ECG in 4 of I I patients but became intermittent in 3
and disappeared in 4 patients .
Five of the 16 patients with Wolff-Parkinson-White syn-
drome had a "non-life-threatening'' proarrhvthmic effect
(Fig . /) . All five of these patients had had paroxysmal
episodes of rapid supraventricular tachycardia before admin-
istration of flecainide and had the onset of an incessant
slower orthodromic supraventricular tachycardia while re-
ceiving flecainide . The incessant tachycardia stopped spon-
taneously in all with discontinuation of flecainide . Four of
the five patients were >5 years of age and one was a
newborn . There was no apparent predictive value for effi-
cacy or proarrhythmia in patients with Wolff-Parkinson-
White syndrome on the basis of known or presumed acces-
sory connection location, rate of initial tachycardia,
flecainide dose per square meter or age .
Nine patients had orthodromic supraventricular tachy-
cardia secondary to a concealed accessory connection .
Flecainide controlled or partially controlled the tachyar-
rhythmia in seven. Two patients whose tachycardia was not
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controlled were 6 and 17 years of age and had poor response
to flecainide treatment without proarrhythmic effect .
Permanent form of junctional reciprocating tachycardia .
Six of the seven patients with the permanent form of
junctional reciprocating tachycardia had excellent control of
tachycardia, whereas one patient had partial control with
long periods of sinus rhythm and slow junctional reciprocat-
ing tachycardia . Of five patients with typical AV node
reentry supraventricular tachycardia, two had control and
three had partial control .
Junctional ectopic tachycardia and atrial flutter . Flecain-
ide was not effective in one patient with junctional ectopic
tachycardia who had undergone aortic valve replacement
several years previously . It was not effective in a patient
with atrial flutter after the Mustard procedure and resulted in
fewer but persistent episodes of atrial flutter in an additional
patient several years after repair of total anomalous pulmo-
nary venous connection .
Atrial ectopic tachycardia and chaotic atrial tachycardia .
In 13 patients with atrial ectopic tachycardia, flecainide
administration resulted in control (sinus rhythm) in  , partial
control in 3 and no significant effect in 1 . This includes a total
of five patients with infantile chaotic atrial tachycardia, a
rapid irregular tachycardia with components of rapid atrial
flutter and fibrillation and atrial ectopic tachycardia (Fig . 2) .
Four of these patients had a normal heart and one had
cardiomyopathy . This arrhythmia was particularly sensitive
to oral flecainide, usually disappearing after the first few
doses at 100 mg/m'- per day . The patient with partial control
was a dysmorphic infant with a severe form of hypertrophic
cardiomyopathy who died of causes secondary to respira-
tory failure and sepsis after exploratory thoracotomy for a
mediastinal mass . Accurate echocardiographic assessment
of the effect of flecainide on ventricular function was not
possible in this patient .
JACC Vol
. 14, No . I
July 1 8   185- 1
Figure 2 . Chaotic atrial tachycardia in a newborn in-
fant. These tracings show elements of ectopic atrial
rhythm, atrial fibrillation and atrial flutter (to 580 beats/
min) with variable atrioventricular block .
Ventricular tachycardia. There were 10 patients with
ventricular tachycardia . Six patients had a normal heart, one
had cardiomyopathy, two had postoperative ventricular sep-
ta) defect and one had complex cyanotic congenital heart
disease. One patient, a 1 year old infant, had a typical
presentation for a myocardial hamartoma but was not taken
to surgery because of successful antiarrhythmic efficacy .
Pharmacokinetic Results
Oral absorption . The mean (+SD) time to peak serum
concentration (T,,, ax ) for all patients was 2 .7 ± 1 .5 h and the
mean maximal plasma concentration (C,„ ax ) after the single
25 mg/m' oral doses was 88 ± 21 ng/ml . Thus, the oral
absorption of flecainide in pediatric patients is relatively
prompt and is likely to be extensive .
Plasma elimination half-life (t 1/2) . The average plasma
t 1/2 was  .6 ± 3 .2 h. However, when patients were
separated into groups of those aged < 1 year, I to 12 years
and > 12 years (Fig. 3), it was shown that the t 1/2 values in
the first and last groups were both significantly longer than
Figure 3 . Plasma flecainide elimination half-life (t 1/2) versus age .
See text for description .
JACC Vol . 14 . No . I
July 1 8   185- 1
Figure 4 . Plasma flecainide clearance (Cl
.)
versus age . See text for
description .
those in the middle group (p < 0 .05) . Similarly, the patients
< I year or > 12 years of age had significantly slower plasma
flecainide clearance than did the I to 12 year old group (Fig .
4) . Seven patients benefited from a change to an every 8 h
dosing schedule to prevent occurrence of breakthrough
tachycardia before drug administration on the every 12 h
regimen . In these patients, the total daily dose was kept
constant but divided in an 8 h schedule . Five of these seven
patients had incessant arrhythmia and all were young (aged
3 months to 3 .5 years) . There was no difference between the
total flecainide dose of these seven patients (134 ± 35 mg/m 2
per day) and that of the patients on an every 12 h dosing
schedule (142 ± 36 mg/m' per day) . Flecainide elimination
half-life, available in two patients aged I year and 20 months,
was  .  and 6 .5 h, respectively. The mean volume of
distribution for all patients was   .5 ± 2 .6 liter/kg ; there were
no differences in this value by age group .
In those patients who had complete 24 h urine collections,
the percent of a single oral dose excreted in urine as
unchanged flecainide ranged from 17% to 47% .
Flecainide serum trough values . For the entire group
these ranged from 0 .1 to 0 .   µg/ml (mean = 0 .36 µg/ml) .
There were no statistical differences in flecainide trough
level among patients with control, partial control or no
control of arrhythmia with serum levels of 0 .36 ± 0 .24,
0.41 ± 0.15 and 0.3 0 ± 0.023 µg/ml, respectively . There
was somewhat better correlation of trough flecainide level
with a dosing schedule based on body surface area (mg/m'
per day) than on body weight (mg/kg per day) (correlation
coefficient [r] = 0 .63 versus 0 .51, respectively) . When
grouped by age, there were marked disparities in r values for
flecainide trough versus dose per square meter . Correlation
coefficient values for the 0 to 1 year, I to 12 year and > 12
year age groups were 0.30, 0 .48 and 0.85, respectively .
Serum digoxin levels . Eleven patients also received di-
goxin during flecainide therapy ; seven had empiric decreases
in their digoxin dose by 25% before drug initiation . Of the
four patients who continued on steady dose, there were no
significant changes in serum digoxin concentration . Patients
who remained on digoxin were not distinguished by age,
arrhythmia type, cardiac size or function .
PERRY ET AL .
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Other Drug Efec'ts
Electrocardiographic changes. The predominant ECG ef-
fects were an average increase in the PR interval by 23 ± 11
ms (a 13% average increase over preflecainide intervals) and
a 17 ± I 1 ms (24%) average increase in the QRS duration .
Increases in the QT interval were secondary to increases in
the QRS duration. No patient had excessive increases in
ECG measurements that required decreasing the dose of
flecainide or discontinuation of therapy .
Proarrhythmia. No life-threatening proarrhythmia oc-
curred in any patient . All five patients in whom flecainide
had a proarrhythmic effect had overt Wolff-Parkinson-White
conduction in normal sinus rhythm and paroxysmal episodes
of orthodromic supraventricular tachycardia . The youngest
patient, aged I week, had had frequent episodes of tachy-
cardia since birth . Proarrhythmia in every patient consisted
of development of an incessant orthodromic supraventricu-
lar tachycardia at a rate slower than the tachycardia seen
before flecainide therapy was started (before 210/min, after
175/min). In all, proarrhythmia occurred during the initiation
phase of flecainide at doses of  0 to 150
Mg/M2
per day and
was well tolerated hemodynamically . There was no predi-
lection for age (7 days to 26 years), gender (3 male, 2 female)
or site of accessory connection when the variables were
compared with those in patients with Wolff-Parkinson-White
syndrome who did not have proarrhythmia . No proarrhyth-
mias were seen during long-term therapy in any patient .
Echocardiographic changes . It is not appropriate to as-
sess changes in echocardiographic ventricular size and con-
tractility in patients with abnormal impulse propagation,
such as patients with incessant ventricular arrhythmia (ab-
normal QRS complexes) or pre-excitation . Therefore, we
have restricted echocardiographic data reporting to those
patients with incessant atrial ectopic tachycardia, infantile
chaotic atrial tachycardia and permanent junctional recipro-
cating tachycardia. As a group, patients with these three
arrhythmias had an average increase in left ventricular
end-diastolic diameter of 8% and no patient had an increase
>8 mm. There was an average decrease in left ventricular
shortening fraction of 2% units if two patients with dramat-
ically improved shortening fractions are excluded . One of
these was a 13 year old who had atrial ectopic tachycardia
and preflecainide left ventricular shortening fraction of 6% to
8%. With therapy and a resumption of sinus rhythm, this
patient's shortening fraction improved to 2 % . A newborn
with chaotic atrial tachycardia had a shortening fraction of
26% that improved to 40% after flecainide . These two
patients had the lowest left ventricular shortening fraction of
the group before therapy and no patient had a >5% unit
reduction after flecainide . No patient included in this report
had an increase in left ventricular end-diastolic dimension or
decrease in left ventricular shortening fraction greater than
those from the groups just mentioned .
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Side effects . Two patients reported that blurred vision
occurred approximately 2 h after administration of oral
flecainide dose. This symptom resolved spontaneously in
one and after a decrease in dose in another . A 15 month old
patient was unsteady on her feet, could not grasp a bottle
well and was irritable 2 .5 h after oral flecainide administra-
tion . These symptoms may have reflected blurry vision and
resolved after two times a day dosing was changed to three
times a day dosing at the same cumulative daily dose . Two
patients (aged 18 months and 3 years, respectively) were
reportedly hyperactive in the first month of therapy, but
these symptoms resolved spontaneously .
A teenage patient, in an apparent suicide attempt, in-
gested a single dose of 2 g of flecainide (equal to  34 mg/m 2 ) .
At 2 to 3 h after ingestion, this patient experienced head-
ache, blurred vision and gastrointestinal distress at a serum
flecainide concentration of 2 .10 µg/ml . The symptoms re-
solved within 12 h with usual ingestion therapy (charcoal,
magnesium citrate) .
Discussion
In this report we have demonstrated the spectrum of
antiarrhythmic efficacy of flecainide in young patients and
have documented important differences between the oral
pharmacokinetics of this drug in children and adults that will
affect appropriate dosing .
Efficacy in supraventricular tachycardia . The efficacy of
oral flecainide in treating reentrant supraventricular tachy-
cardia involving an accessory connection has been reported
in adults (11) and a small series of children (I) . Flecainide
slows conduction in both the AV node and accessory con-
nections and prolongs the anterograde and retrograde acces-
sory connections refractory periods . Therefore, the drug is
appealing for treatment of patients with Wolff-Parkinson-
White conduction and supraventricular tachycardia because
both "limbs" of the circuit are affected . Seventeen of 25
patients with overt or concealed Wolf Parkinson-White
conduction had excellent control of tachycardia episodes .
The development of proarrhythmia as an event specific to
patients with overt Wolff-Parkinson-White conduction has
not been stressed in previously published reports . It is
possible that early in the course of flecainide initiation,
conduction in the accessory pathway or AV node, or both,
was slowed to a degree whereby the conditions of reentry
(albeit at a longer cycle length) were more favorable and
"proarrhythmia" occurred . It is also possible that in some
patients further increases in flecainide dose beyond this
initial range will slow conduction further and thereby elimi-
nate tachycardia. Such increases were not attempted in our
series .
Three pediatric arrhythmias deserve special comment
 
the permanent form of junctional reciprocating tachycardia,
atrial ectopic tachycardia and infantile chaotic atrial tachy-
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cardia . Each of these arrhythmias tends to be incessant
pediatric tachyarrhythmia that increases the risk of develop-
ing poor ventricular function and cardiomyopathy (12) .
Flecainide was particularly effective in treating these ar-
rhythmias (control or partial control in 1  of 20 patients),
terminating tachycardia early in the course of initiation
therapy ( 0 to 150 mg/m` per day) . Equally important, the
return to normal sinus rates in these patients brought about
gradual improvement in cardiac contractility, and the de-
creases in function reported in adult patients were not seen
(13) .
Efficacy in ventricular tachycardia . The efficacy of flec-
ainide in ventricular tachycardia bears some similarity to
that reported in adult series (14,15), but important additions
particular to pediatric patients exist . Though ventricular
tachycardia may prove to involve a different underlying
anatomic substrate in children, it appears to be as well
controlled by flecainide as are adult ventricular arrhythmias .
Ventricular arrhythmias tend to be uncommon in children
who had not had intracardiac surgery, but only 2 of 10
patients with ventricular tachycardia in our series had a
previous open heart procedure (closure of ventricular septal
defect) . His-Purkinje conduction can be markedly affected
by flecainide, which may prolong the HV interval beyond the
normal range in the majority of adult patients (16). We were
reluctant, therefore, to use this agent in some of the more
common postoperative settings in which pediatric ventricu-
lar arrhythmias occur (e .g ., postoperative tetralogy of Fal-
lot), because many patients in such settings have baseline
HV prolongation . As intracardiac electrophysiologic studies
were not part of this protocol, we cannot comment on the
effect of flecainide on the HV interval in our patients .
One patient, a 1 year old, had a suspected ventricular
tumor (17) causing ventricular tachycardia but responded to
flecainide . No other patient in this series had a ventricular
tumor. A 14 month old patient (not in this report) referred to
us for ventricular tachycardia had been treated with
flecainide at another institution unsuccessfully and was
found at surgery to have a ventricular tumor as described in
earlier patients from our center .
Pharmacokinetics . We emphasize the oral pharmacoki-
netic data presented in this report because they provide
guidelines for pediatric oral dosing of flecainide . Infants <1
year of age tended to have an elimination half-life (t 1/2) for
flecainide that was similar (I 1 to 12 h) to that of children > 12
years of age and healthy adults. However, in the age range of
1 to 12 years, t 1/2 was approximately 8 h .
The longer plasma t 1/2 in many of the very young
patients may be due to not yet fully developed hepatic and
renal clearance mechanisms ; flecainide is reported to be
cleared extensively from the body via hepatic biotransfor-
mation and renal excretion ( ,18) . Because the plasma t 1/2
values for four of the six patients < 1 year of age were
determined after multiple dosing, it may be possible that the
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longer t 1/2 observed for this group was due to a reduction in
the clearance of flecainide with long-term dosing . However,
this seems unlikely because the plasma t 1/2 for flecainide in
pediatric patients after long-term multiple dosing has been
reported to be not different from that observed after single
doses (Till JA, personal communication) . The longer t 1/2
values observed in the patients >12 years of age may be
associated with physiologic changes that commonly occur
with the onset of adolescence .
The time to peak serum concentrations (T,,,,,,) and max-
imal serum concentrations are in good agreement
with previously reported values for adult patients . The
tendency for slower plasma flecainide clearance in the
youngest and oldest groups is consistent with the longer
plasma t 1/2 observed in those groups . Mean plasma
flecainide clearance in these patients was also similar to that
previously reported for adult subjects .
The low correlation coefficient for serum trough flecain-
ide level versus dose in patients <I year of age reflects a
wide scatter of values in this group . Pharmacodynamics are
probably highly variable in this age range and further delin-
eation of the kinetics of flecainide seems indicated in these
young patients .
The paucity of side e ects and lack of negative hemodv-
namic effect in our series is encouraging
. It does not appear
that empiric reduction in digoxin dose . which has been
recommended for adult patients, is warranted in all pediatric
patients receiving flecainide . Additionally, a wide therapeu-
tic/toxic ratio may be inferred from the overdose incident,
wherein the adolescent ingested nearly 10 times the usual
total daily dose without deleterious cardiovascular effect .
Conclusions . 1) Flecainide was effective therapy in pedi-
atric patients with the permanent form of junctional recipro-
cating tachycardia, atrial ectopic and infantile chaotic atrial
tachycardia, selected patients with ventricular tachycardia
and most patients with reentrant supraventricular tachycar-
dia. 2) Some patients with Wolf-Parkinson-White syndrome
and supraventricular tachycardia developed an asymptom-
atic, incessant, slower orthodromic tachycardia while re-
ceiving flecainide during initiation of therapy and it was not
possible to predict this result . 3) Flecainide resulted in rare
side effects and no negative hemodynamic effects in these
patients . 4) Infants and children aged I to 12 years tended to
have a shorter flecainide elimination half-life and more rapid
plasma clearance than did infants < 1 year of age and older
children  Dosing 3 times daily may be beneficial in this age
group. Further investigation of the pharmacokinetics of
flecainide in patients < I year of age is needed . We recom-
mend, in the pediatric population, in-hospital initiation of
flecainide therapy with incremental dosing titrated to re-
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sponse and based on body surface area rather than body
weight .
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References
I . Ward DE . Jones S, Shinebourne EA . Use of flecainide acetate for
refractory junctional tachycardias in children with the Wolff-
Parkinson-White syndrome . Am J Cardiol 1 86  57  787- 0 .
Wren C . Campbell RW . The response of paediatric arrhythmias to
intravenous and oral flecainide . Br Heart J 1 87  57  171-5 .
3 . Zeigler V, Gillette PC . Hammill B . Ross BA . Ewing L . Flecainide for
supraventricular tachycardia in children . Am J Cardiol 1 88  62  41D-3D .
4 . Holmes B, Heel RC . Flecainide . A preliminary review of its pharmaco-
dynamic properties and therapeutic efficacy . Drugs 1 85
 2 
 1-33
.
5 . The Flecainide-Quinidine Research Group . Flecainide versus quinidine
for treatment of chronic ventricular arrhythmias . A multicenter clinical
trial . Circulation 1 83  67  1117-23 .
6 . Neuss H . Buss J . Schlepper M, et al . Effects of flecainide on electrophys-
iologic properties of accessory pathways in the Wolff-Parkinson-White
syndrome . For Heart J 1 83  4  347-53 .
7 . Garson A Jr . Dosing the newer antiarrhythmic drugs in children   consid-
erations in pediatric pharmacology (editorial) . Am J Cardiol 1 86  
57  1405-7 .
8 . Chang SF, Miller AM, Fox JM, Welscher TM . Determination of
flecainide in human plasma by high performance liquid chromatography
with fluorescence detection . J Liq Chromatogr 1 84  7  167-76 .
  . Conard GJ . Ober RE . Metabolism of flecainide . Am J Cardiol 1 84  
53  41B-5IB .
10 . Shumaker RC . PKCALC  A basic interactive computer program for
statistical and pharmacokinetic analysis of data . Drug Metab Rev 1 86  
17  331-48 .
11 . Kim SS, Lal R, Ruffy R
. Treatment of paroxysmal reentrant supraven-
tricular tachycardia with flecainide acetate
. Am J Cardiol 1 86  58 80-5 .
12 . Gillette DA, McNamara DG . Chronic supraventricular tachycardia . A
curable cause of congestive cardiomyopathy . JAMA 1 85  253  3 1-2 .
13 . Josephson MA, Ikeda N. Singh BH . Effects of flecainide on ventricular
function   clinical and experimental correlations . Am J Cardiol 1 84  
53   5B-I(X)B .
14 . Anderson JL, Stewart JR, Perry BA, et al . Oral flecatmde acetate for the
treatment of ventricular arrhythmias . N Engl J Med 1 81  305  473-7 .
15 . Platia EV . Estes NAM, Heine DL, et al . Flecainide   electrophysiologic
and antiarrhythmic properties in refractory ventricular tachycardia
. Am J
Cardiol 1 85
 55
  56-62 .
16 . Estes NAM . Garan H. Ruskin JN . Electrophysiologic properties of
flecainide acetate . Am J Cardiol 1 84 ;53  26B- B .
17 . Garson A Jr . Smith RT Jr, Moak JP, et al . Incessant ventricular
tachycardia in infants   myocardial harmartomas and surgical cure . J Am
Coll Cardiol 1 87  10  61 -26 .
18 . McQuinn RL, Quarfoth GJ, Johnson JD, et al . Biotransformation and
elimination of 14 C-flecainide acetate in humans . Drug Metab Dispos
1 84  12  414-20 .
